Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-1926

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor ; day:18 ; month:4 ; year:2020 ; pages:1-18
Clinical pharmacokinetics ; (18.4.2020), 1-18

Creator: James, Angela Joubert
Smith, Catherine C.
Litzow, Mark
Perl, Alexander E.
Altman, Jessica K.
Shepard, Dale
Kadokura, Takeshi
Souda, Kinya
Patton, Melanie
Lu, Zheng
Liu, Chaofeng
Moy, Selina
Levis, Mark J.
Bahceci, Erkut

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40262-020-00888-w

URN: urn:nbn:de:101:1-2020062923565702717642

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

James, Angela Joubert
Smith, Catherine C.
Litzow, Mark
Perl, Alexander E.
Altman, Jessica K.
Shepard, Dale
Kadokura, Takeshi
Souda, Kinya
Patton, Melanie
Lu, Zheng
Liu, Chaofeng
Moy, Selina
Levis, Mark J.
Bahceci, Erkut
SpringerLink (Online service)

Other Objects (12)

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Newer Tyrosine Kinase Inhibitors for CML

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Second-generation inhibitors of Bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

Hochschulschrift

The effects of tyrosine kinase inhibitors in pancreatic cancer

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Newer Tyrosine Kinase Inhibitors for CML

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Second-generation inhibitors of Bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

Hochschulschrift

The effects of tyrosine kinase inhibitors in pancreatic cancer

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Newer Tyrosine Kinase Inhibitors for CML

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Second-generation inhibitors of Bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

Hochschulschrift

The effects of tyrosine kinase inhibitors in pancreatic cancer

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Newer Tyrosine Kinase Inhibitors for CML

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Second-generation inhibitors of Bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

The effects of tyrosine kinase inhibitors in pancreatic cancer

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Newer Tyrosine Kinase Inhibitors for CML

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Second-generation inhibitors of Bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

The effects of tyrosine kinase inhibitors in pancreatic cancer

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Newer Tyrosine Kinase Inhibitors for CML

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Second-generation inhibitors of Bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

The effects of tyrosine kinase inhibitors in pancreatic cancer

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

Related objects

Reset password